长春高新：子公司褪黑素颗粒上市申请获受理

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the registration application of melatonin granules, indicating progress in the approval process for this pediatric product [1] Group 1: Company Developments - The melatonin granules are developed by Jinsai Pharmaceutical and are intended for use in the pediatric neuropsychiatric field [1] - This product is classified as a Class 4 chemical drug and aims to improve sleep difficulties associated with neurodevelopmental disorders in children [1] - The mechanism of action involves activating the MT1 and MT2 receptors in the suprachiasmatic nucleus to regulate neural activity, demonstrating sleep-inducing effects [1]